Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Abstract

12Shire, Cambridge, MA Key Points• First-in-human, phase 1 study, recombinant ADAMTS-13 was safe, nonimmunogenic, and tolerated in congenital thrombotic thrombocytopenic purpura.• Recombinant ADAMTS-13 pharmacokinetic profile was comparable to plasma infusion studies, with evidence of pharmacodynamic activity.Safety, tolerability, and pharmacokinetics of recombinant ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; BAX 930; SHP655) were investigated in 15 patients diagnosed with severe congenital ADAMTS-13 deficiency (plasma ADAMTS-13 activity <6%) in a prospective phase 1, first-in-human, multicenter dose escalation study. BAX 930 was well tolerated, no serious adverse events occurred, and no anti-ADAMTS-13 antibodies were observed. After single-dose administration of BAX 930 at 5, 20, or 40 U/kg body weight to adolescents and adults, there was approximate dose proportionality with respect to maximum plasma concentration (C max [U/mL]) and area under the concentration-time curve (AUC [h•U/mL]). Dose-related increases of individual ADAMTS-13:Ag and activity were observed and reached a maximum within 1 hour. With escalating BAX 930 doses administered, a dose-dependent persistence of ADAMTS-13-mediated von Willebrand factor (VWF) cleavage products and reduced VWF multimeric size were observed. This study demonstrated that pharmacokinetic parameters of BAX 930 were comparable to those estimated in previous plasma infusion studies and provided evidence of pharmacodynamic activity. This study was registered at www.

Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience

“…Caplacizumab, a nanobody that blocks von Willebrand factor interaction with platelets, can promptly prevent 15 Recombinant ADAMTS13 will provide ADAMTS13 activity to decrease the concentration of ultra-large von Willebrand factor multimers. 16 These new treatments may provide a major benefit for Jehovah's Witness patients.…”

Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand

“…In vitro, this agent restores the VWF‐cleaving capacity of congenitally ADAMTS13‐deficient plasma, and neutralises ADAMTS13 antibodies in plasma of patients with acquired TTP . Safety was demonstrated in a study of 15 patients with congenital TTP …”

Pediatric thrombotic thrombocytopenic purpura

“…The third therapeutic target is von Willebrand factor. Caplacizumab has been recently evaluated in a phase III trial devoted to adult TTP patients . N‐acetylcystein is currently in progress in pediatric TTP [Colour figure can be viewed at wileyonlinelibrary.com]…”